HC

Hyung Chun

Adjunct Professor at Stanford University School of Medicine

New Haven, Connecticut

Overview 

Hyung Chun is a Partner at Foresite Capital Management, with a background in higher education and research. Notable career highlights include serving as an Adjunct Associate Professor at Yale University School of Medicine and investing in companies like Latigo Biotherapeutics at the Series A stage.

Work Experience 

  • Partner

    2021 - Current

Foresite Capital is a healthcare and life sciences investment firm.

  • Adjunct Associate Professor

    2022

  • Associate Professor of Medicine and Pathology with Tenure

    2019 - 2022

  • Co-Director, Yale Cardiovascular Research Center

    2021 - 2021

  • Associate Professor of Medicine

    2015 - 2019

  • Assistant Professor

    2009 - 2015

  • Board Member

    2022

Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain.

Raised $150,000,000.00 from Corner Ventures, 5AM Ventures, Westlake Village BioPartners and Foresite Capital.

  • Board Observer

    2021

Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.

Raised $487,000,000.00 from Fidelity, T. Rowe Price, HBM Healthcare Investments, Global BioAccess Fund, Foresite Capital, The Healthcare Innovation Investment, General Catalyst, Woodline Partners, Ascenta Capital and BlackMars Capital.

  • Chief Cardiology Fellow

    2008 - 2009

  • Cardiology Fellow

    2004 - 2009

  • Internal Medicine Resident

    2002 - 2004

  • HHMI/NIH Research Scholar

    1999 - 2001

National Institutes of Health is a biomedical research facility that focuses on biomedical and health-related research.

Raised $5,000,000.00 from National Institute of Allergy and Infectious Diseases.

Articles About Hyung

Relevant Websites